141 related articles for article (PubMed ID: 38536641)
1. Gut microbiota dynamics in KK-Ay mice: restoration following antibiotic treatment.
Hong J; Fu T; Liu W; Yu M; Lin Y; Min C; Lin D
Folia Microbiol (Praha); 2024 Mar; ():. PubMed ID: 38536641
[TBL] [Abstract][Full Text] [Related]
2. Specific Alternation of Gut Microbiota and the Role of
Hong J; Fu T; Liu W; Du Y; Bu J; Wei G; Yu M; Lin Y; Min C; Lin D
J Microbiol Biotechnol; 2024 Mar; 34(3):547-561. PubMed ID: 38346799
[TBL] [Abstract][Full Text] [Related]
3. Compound Danshen Dripping Pills moderate intestinal flora and the TLR4/MyD88/NF-κB signaling pathway in alleviating cognitive dysfunction in type 2 diabetic KK-Ay mice.
Fan X; Zhang Y; Song Y; Zhao Y; Xu Y; Guo F; Shao M; Ma X; Zhang W; Wei F; Qin G
Phytomedicine; 2023 Mar; 111():154656. PubMed ID: 36682300
[TBL] [Abstract][Full Text] [Related]
4. Diosmetin ameliorate type 2 diabetic mellitus by up-regulating Corynebacterium glutamicum to regulate IRS/PI3K/AKT-mediated glucose metabolism disorder in KK-Ay mice.
Gong X; Xiong L; Bi C; Zhang B
Phytomedicine; 2021 Jul; 87():153582. PubMed ID: 34091150
[TBL] [Abstract][Full Text] [Related]
5. Changes in Synaptic Plasticity and Glutamate Receptors in Type 2 Diabetic KK-Ay Mice.
Yin H; Wang W; Yu W; Li J; Feng N; Wang L; Wang X
J Alzheimers Dis; 2017; 57(4):1207-1220. PubMed ID: 28304288
[TBL] [Abstract][Full Text] [Related]
6. Studies of pathology and pharmacology of diabetic encephalopathy with KK-Ay mouse model.
Shi S; Yin HJ; Li J; Wang L; Wang WP; Wang XL
CNS Neurosci Ther; 2020 Mar; 26(3):332-342. PubMed ID: 31401815
[TBL] [Abstract][Full Text] [Related]
7. Diabetic bladder dysfunction in T2D KK-Ay mice and its changes in the level of relevant gene expression.
Zhang J; Zhang Y; Yang X; Wang J; Xu Y; Wang R; Tan B; Huang P; Cao H
Biomed Pharmacother; 2020 Nov; 131():110706. PubMed ID: 33152907
[TBL] [Abstract][Full Text] [Related]
8. Increased methylmercury toxicity related to obesity in diabetic KK-Ay mice.
Yamamoto M; Yanagisawa R; Motomura E; Nakamura M; Sakamoto M; Takeya M; Eto K
J Appl Toxicol; 2014 Aug; 34(8):914-23. PubMed ID: 24243536
[TBL] [Abstract][Full Text] [Related]
9. Diabetic nephropathy in KK and KK-Ay mice.
Okazaki M; Saito Y; Udaka Y; Maruyama M; Murakami H; Ota S; Kikuchi T; Oguchi K
Exp Anim; 2002 Apr; 51(2):191-6. PubMed ID: 12012732
[TBL] [Abstract][Full Text] [Related]
10. Dynamic Phenotypes and Molecular Mechanisms to Understand the Pathogenesis of Diabetic Nephropathy in Two Widely Used Animal Models of Type 2 Diabetes Mellitus.
Liu Y; Huang H; Gao R; Liu Y
Front Cell Dev Biol; 2020; 8():172. PubMed ID: 32266256
[TBL] [Abstract][Full Text] [Related]
11. Suramin prevents the development of diabetic kidney disease by inhibiting NLRP3 inflammasome activation in KK-Ay mice.
Oda K; Miyamoto S; Kodera R; Wada J; Shikata K
J Diabetes Investig; 2023 Feb; 14(2):205-220. PubMed ID: 36308062
[TBL] [Abstract][Full Text] [Related]
12. Morphological characterization of systemic changes in KK-Ay mice as an animal model of type 2 diabetes.
Moroki T; Yoshikawa Y; Yoshizawa K; Tsubura A; Yasui H
In Vivo; 2013; 27(4):465-72. PubMed ID: 23812216
[TBL] [Abstract][Full Text] [Related]
13. JiangTang XiaoKe granule attenuates cathepsin K expression and improves IGF-1 expression in the bone of high fat diet induced KK-Ay diabetic mice.
Guo Y; Wang L; Ma R; Mu Q; Yu N; Zhang Y; Tang Y; Li Y; Jiang G; Zhao D; Mo F; Gao S; Yang M; Kan F; Ma Q; Fu M; Zhang D
Life Sci; 2016 Mar; 148():24-30. PubMed ID: 26892148
[TBL] [Abstract][Full Text] [Related]
14. Toxicokinetics of methylmercury in diabetic KK-Ay mice and C57BL/6 mice.
Yamamoto M; Yanagisawa R; Sakai A; Mogi M; Shuto S; Shudo M; Kashiwagi H; Kudo M; Nakamura M; Sakamoto M
J Appl Toxicol; 2021 Jun; 41(6):928-940. PubMed ID: 33015845
[TBL] [Abstract][Full Text] [Related]
15. Identification of quantitative trait loci for diabetic nephropathy in KK-Ay/Ta mice.
Aoki T; Kaneko S; Tanimoto M; Gohda T; Hagiwara S; Murakoshi M; Ishikawa Y; Furukawa M; Funabiki K; Horikoshi S; Tomino Y
J Nephrol; 2012; 25(1):127-36. PubMed ID: 21725918
[TBL] [Abstract][Full Text] [Related]
16. Xanthine Oxidase Inhibitor Febuxostat Exerts an Anti-Inflammatory Action and Protects against Diabetic Nephropathy Development in KK-Ay Obese Diabetic Mice.
Mizuno Y; Yamamotoya T; Nakatsu Y; Ueda K; Matsunaga Y; Inoue MK; Sakoda H; Fujishiro M; Ono H; Kikuchi T; Takahashi M; Morii K; Sasaki K; Masaki T; Asano T; Kushiyama A
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31546603
[TBL] [Abstract][Full Text] [Related]
17. Amelioration of bone fragility by pulsed electromagnetic fields in type 2 diabetic KK-Ay mice involving Wnt/β-catenin signaling.
Shao X; Yang Y; Tan Z; Ding Y; Luo E; Jing D; Cai J
Am J Physiol Endocrinol Metab; 2021 May; 320(5):E951-E966. PubMed ID: 33719588
[TBL] [Abstract][Full Text] [Related]
18. Lessons From the KK-Ay Mouse, a Spontaneous Animal Model for the Treatment of Human Type 2 Diabetic Nephropathy.
Tomino Y
Nephrourol Mon; 2012; 4(3):524-9. PubMed ID: 23573479
[TBL] [Abstract][Full Text] [Related]
19. Anti-diabetic effects of globin digest and its active ingredient Leu-Ser-Glu-Leu in ICR mice, streptozotocin-induced diabetic mice and KK-Ay mice.
Nakaoka F; Sasakawa Y; Yamamoto K; Nakao M; Nakamura M; Tong C; Fukuhama C; Kagawa K
Life Sci; 2010 Mar; 86(11-12):424-34. PubMed ID: 20109472
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of neurobehavioral impairment in methylmercury-treated KK-Ay mice by dynamic weight-bearing test.
Yamamoto M; Motomura E; Yanagisawa R; Hoang VAT; Mogi M; Mori T; Nakamura M; Takeya M; Eto K
J Appl Toxicol; 2019 Feb; 39(2):221-230. PubMed ID: 30175511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
